Tvardi is a cash-backed, negative-enterprise-value STAT3 platform whose fate hinges on whether TTI-109 can rescue tolerability and TTI-101 can validate oncology efficacy in 2026.
Overview
Tvardi Therapeutics is a clinical-stage biotech developing oral small-molecule STAT3 inhibitors for cancer, fibrosis, and inflammatory disease. After an 83.9% stock collapse tied to the failed Phase 2 IPF trial, the market now values the company below cash, effectively assigning negative value to its pipeline. Yet post-hoc IPF data showed evidence of target engagement, including reduced lung fibrosis scores and IL-6 declines. Upcoming 2026 catalysts—TTI-109 healthy volunteer data and TTI-101 hepatocellular carcinoma results—create a highly speculative but asymmetric setup.